| Neuroprotection in subarachnoid hemorrhage. | |
| | |
MedLine Citation:
|
PMID: 20876512 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite advances in aneurysm ablation and the initial management of patients presenting with aneurysmal subarachnoid hemorrhage, delayed cerebral ischemia remains a significant source of morbidity. Traditionally, delayed cerebral ischemia was thought to be a result of vasospasm of the proximal intracranial vessels, and clinical trials have relied largely on radiographic evidence of vasospasm as a surrogate for functional outcome. However, a number of trials have demonstrated a dissociation between angiographic vasospasm and outcome, and more recent data suggest that other mechanisms of injury, such as microvascular dysfunction and complex neuronal-glial interactions, may influence the development of delayed ischemic deficit after aneurysmal subarachnoid hemorrhage. Our evolving understanding of the pathophysiology of delayed cerebral ischemia may offer the opportunity to test new therapeutic strategies in this area and improve clinical trial design. |
| | |
Authors:
|
Daniel T Laskowitz; Brad J Kolls |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Stroke; a journal of cerebral circulation Volume: 41 ISSN: 1524-4628 ISO Abbreviation: Stroke Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-09-29 Completed Date: 2010-11-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0235266 Medline TA: Stroke Country: United States |
Other Details:
|
Languages: eng Pagination: S79-84 Citation Subset: IM |
Affiliation:
|
Departments of Medicine Neurology, Duke University, Durham NC 27710, USA. danl@neuro.duke.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Brain
/
blood supply Humans Neuroprotective Agents / therapeutic use* Subarachnoid Hemorrhage / drug therapy* Vasospasm, Intracranial / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Neuroprotective Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Modulation of the postischemic immune response to improve stroke outcome.
Next Document: Can molecular and cellular neuroprotection be translated into therapies for patients?: yes, but not ...